In breast cancer, pitavastatin reduced the mevalonate and PPARγ signaling pathways, leading to partial reversal of epithelial-mesenchymal transition by inhibiting Snail and matrix metalloproteinase 9 (Wang et al. 2019). Here, PPARG is linked to breast carcinoma.